Compugen (NASDAQ:CGEN) Stock Passes Above Two Hundred Day Moving Average – Should You Sell?

Compugen Ltd. (NASDAQ:CGEN) shares crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $2.28 and traded as high as $2.50. Compugen shares last traded at $2.41, with a volume of 279,975 shares.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. HC Wainwright reaffirmed a “buy” rating on shares of Compugen in a report on Tuesday, August 4th. Weiss Ratings raised shares of Compugen from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Wednesday, August 5th. Wall Street Zen lowered shares of Compugen from a “buy” rating to a “hold” rating in a research report on Saturday, May 23rd. Finally, Leerink Partners lowered their price target on shares of Compugen from $13.00 to $5.00 and set an “outperform” rating on the stock in a research report on Thursday, May 21st. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $5.00.

Compugen Price Performance

The stock has a 50-day moving average of $2.25 and a 200 day moving average of $2.28. The stock has a market cap of $227.87 million, a PE ratio of 6.34 and a beta of 2.77.

Compugen (NASDAQ:CGEN) last issued its earnings results on Monday, August 3rd. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.01. Compugen had a return on equity of 42.57% and a net margin of 47.56%.The company had revenue of $2.60 million during the quarter, compared to analysts’ expectations of $1.28 million. During the same period in the prior year, the business earned ($0.08) EPS. Research analysts forecast that Compugen Ltd. will post -0.27 EPS for the current fiscal year.

Institutional Investors Weigh In On Compugen

A number of hedge funds have recently modified their holdings of CGEN. Platform Technology Partners increased its position in Compugen by 10.0% during the first quarter. Platform Technology Partners now owns 55,000 shares of the biotechnology company’s stock worth $117,000 after purchasing an additional 5,000 shares during the last quarter. State Street Corp boosted its holdings in Compugen by 3.9% in the 4th quarter. State Street Corp now owns 393,802 shares of the biotechnology company’s stock valued at $603,000 after purchasing an additional 14,701 shares during the last quarter. Two Sigma Investments LP boosted its holdings in Compugen by 10.6% in the 3rd quarter. Two Sigma Investments LP now owns 197,875 shares of the biotechnology company’s stock valued at $291,000 after purchasing an additional 18,929 shares during the last quarter. Glenmede Trust Co. NA grew its stake in shares of Compugen by 187.5% in the 1st quarter. Glenmede Trust Co. NA now owns 34,500 shares of the biotechnology company’s stock valued at $73,000 after buying an additional 22,500 shares during the period. Finally, Bank Hapoalim BM purchased a new stake in shares of Compugen in the 4th quarter valued at approximately $37,000. Hedge funds and other institutional investors own 12.22% of the company’s stock.

Compugen Company Profile

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.